The Prospects Of Personalized Medicine Drive Growth In The Global Human Microbiome Market At A Cagr Of 21.89% By 2027

Triton Market Research presents their Global Human Microbiome market report segmented by products (Probiotics, Foods, Prebiotics, Medical food, Diagnostic Devices, Drugs, Other products); applications (drugs, diagnostics), diseases (Cancer, Obesity, Ulcerative colitis, Crohn’s disease, C. Difficle infection, Lactose intolerance, Dental caries, Type 2 diabetes, Recurrent bacterial vaginosis and UTI, Hyperoxaluria, Urea cycle disorder, Hepatic Encephalopathy, Celiac disease, Phenylketonuria and Non-alcoholic steatohepatitis) and by geographical region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - discussing Industry Value Chain Analysis, Porter's 5 Force Analysis, Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2019-2027).

The human microbiome plays an important role in the pathogenesis of a variety of popular diseases. As a result, several companies in the life science sector are now shifting their focus towards gaining commercial benefits from microbiome-based drugs and diagnostics. Triton Market Research expects the global human microbiome market to witness a compound annual growth rate of 21.89% during the forecast period of 2019-2027.

Human microbiome-based drugs and diagnostics represent a novel approach to tackle some of the tough to treat diseases. In 2007, NIH launched the Human Microbiome Project (HMP), a five-year initiative aimed at cataloging the vast array of microbial genes and species present in the various ecological niches of the body and identifying their role in health and disease. This, in combination with factors such as increased use of personalized medicine, the growing prevalence of chronic diseases globally and increased emphasis on early disease detection, is propelling the market demand for human microbiome. However, lack of technical expertise, barriers in initial analysis and strict government protocols might challenge the market expansion.

Triton Market Research has studied human microbiome markets in the Asia-Pacific, Europe, North America and the rest of the world. The North American region currently accounts for the biggest revenue share and is expected to continue contributing the highest revenue throughout the forecast period. The region is prospering due to heavy funding and research grants from the US and Canadian governments. In the US, the prevalence of diseases like IBS (Irritable bowel syndrome), cancer, obesity, diabetes miletus and other inflammatory and infectious diseases is quite high. As a result, several companies are increasingly investing for the development of novel therapies and diagnostics technique with the help of human microbiome technologies to reduce the prevalence rate of such chronic conditions. In Canada, the market is flourishing due to the funding provided by the Canadian Institute of Health Research (CIHR).

Seeing the future potential of the human microbiome market in the development of personalized medicine, several venture capitalists are investing for developing microbial screening tests, prebiotics, diagnostics and therapeutics. The leading market players profiled by Triton Market Research for the human microbiome market are Metabiomics, 4D Pharma, Avidbiotics Inc., Actogenix NV, Microbiome Therapeutics, Metabogen AB, Avidbiotics Corp., Enterome SA, Miomics, and Osel Inc.